NeoImmuneTech Appoints Jean Fan, M.D., as Chief Clinical Officer
Retrieved on:
Wednesday, August 25, 2021
Health, Other Science, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Industry, IL-7, Company, CCO, GIST, Infection, Medical college, Blueprint, Cancer, Eisai, Sun, Master of Science, Leadership, Drug, Boehringer Ingelheim, PricewaterhouseCoopers, NIT, KOSDAQ, Assistant, Georgetown University School of Medicine, Bristol Myers Squibb, BMS, Clinical trial, International Association for Dance Medicine & Science, Patient, GlaxoSmithKline, Immunity, Medical College of Nanchang University, Novartis, Amgen, Jean Fan, VP, Hematology, FDA, GSK, Nanchang University, Eli Lilly, AstraZeneca, Pharmaceutical industry, NT-I7, NeoImmuneTech, NT-I7, NEOIMMUNETECH
NeoImmuneTech, Inc. (KOSDAQ: 950220), a clinical-stage T cell-focused biopharmaceutical company, today announced the appointment of Jean Fan, M.D., as Chief Clinical Officer (CCO).
Key Points:
- NeoImmuneTech, Inc. (KOSDAQ: 950220), a clinical-stage T cell-focused biopharmaceutical company, today announced the appointment of Jean Fan, M.D., as Chief Clinical Officer (CCO).
- Fan brings over 20 years of experience in oncology and hematology leadership and clinical development to this role.
- Fans contributions to our Clinical Development team thus far, and I am pleased to welcome her to the newly created role of Chief Clinical Officer, said Se Hwan Yang, Ph.D., President and Chief Executive Officer of NeoImmuneTech (NIT).
- Fan joined NIT in 2020 as VP, Head of Clinical Development, coming from Blueprint Medicines where she served as VP, Clinical Development.